Home Top Stories Monitor NDMA levels in antacid Ranitidine: Drugs body CDSCO

Monitor NDMA levels in antacid Ranitidine: Drugs body CDSCO

by Editorial
0 comments

Following reports of NDMA impurity, CDSCO has directed state drug controllers to monitor NDMA levels in Ranitidine, a common antacid. An expert panel recommended a larger committee to investigate storage conditions and ICMR to study the drug's safety. Manufacturers are instructed to monitor NDMA levels and take risk-based measures, potentially reducing shelf life.Original Article

You may also like

Leave a Comment

Laest News

About

We provide timely, accurate, and insightful business news that drives informed decision-making. Our expert coverage spans markets, trends, and strategies to keep you ahead of the curve.

© 2024 – All Rights Reserved. Kryzen Technologies Private Limited